Fresh from the biologic pipeline.
Osborne
Randall
R
D061067:Antibodies, Monoclonal, Humanized; D001709:Biotechnology / Q000331:legislation & jurisprudence* / Q000592:standards*; D002352:Carrier Proteins / Q000009:adverse effects; D000068582:Certolizumab Pegol; D003174:Complement C1 Inactivator Proteins / Q000009:adverse effects; D050718:Complement C1 Inhibitor Protein; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000009:adverse effects; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins / Q000009:adverse effects; D011994:Recombinant Proteins / Q000009:adverse effects; D022243:Rotavirus Vaccines / Q000009:adverse effects; D013917:Thrombin / Q000009:adverse effects / Q000235:genetics; D013926:Thrombopoietin; D014481:United States; D014486:United States Food and Drug Administration; D014613:Vaccines, Attenuated / Q000009:adverse effects
D061067:Antibodies, Monoclonal, Humanized; D002352:Carrier Proteins; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D007140:Immunoglobulin Fab Fragments; C492457:RIX4414 vaccine; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D022243:Rotavirus Vaccines; C469952:SERPING1 protein, human; D014613:Vaccines, Attenuated; D011092:Polyethylene Glycols; C531377:rilonacept; D013926:Thrombopoietin; D013917:Thrombin; C488777:romiplostim; D000068582:Certolizumab Pegol